Indian Pharmaceutical Market

Annual Report – 2022 (Jan-Dec)

Dataset: TSA December 2022

© 2023. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 Market reflected growth of 7% in the year 2022
MAT Progress, Val ₹ ‘000 Cr.
• Overall IPM market size: ₹1,93,838 Cr. (MAT);
Growth in Sales Value :7% (MAT);
• Chronic TAs growth (9% MAT) outperformed Acute TAs growth (5% MAT) in 2022
194
182
147 154
133
• Amongst Chronic TAs, Respiratory registered robust growth of 11% followed by CNS 10%
• Cardiac and Diabetes reflected single digit growth at 7% and 6% resp
• Uro and Pain also registered double digit growth of 16% and 21% respectively.

• Gastro, Pain Acute and Gynae led the growth for Acute TA’s with a growth of 11%, 10% 2018 2019 2020 2021 2022
and 15%
• Antivirals showed -59% degrowth owing to high base in 2021 QTR Progress, Val ₹ ’000 Cr.
• Anti-infectives, VMN and Derma grew in single digits.
10% 8% 10%
-2%
• Relative performance: Indian Pharma Cos grew faster at 7% compared to MNCs which 52 51
grew at 4% in 2022 44
47

• Number of new launches have increased by 2% to 3032 in 2022 as compared to 2021

Q1’22 Q2’22 Q3’22 Q4’22

MAT Dec 2022 vs. MAT Dec 2021 as well as Qtr. Oct-Dec 2022 vs. Qtr. Oct-Dec 2021 growth
Source: IQVIA TSA Dec 2022
1
 Acute

Acute market reflected growth of 5% majorly due to growth from AI, Pain,
Respi Acute and GI therapies
Chronic Acute

IPM 38% 62% 193.8

Anti-Infectives Pain
• MAT growth: Value: 5%; Unit: -1.3% • MAT growth: Value: 10%; Unit: -0.6%
• Cephalosporins, which contributes ~43% of total AI therapy, grew by 8% • Antirheumatic, Nonsteroidal market which contributes to 44% of Pain
6% growth. Macrolides and Quinolones de-grew in single digit at -3% 18% market reflected growth of 10%
and -2% respectively.
• While Anti-Pyretics amongst largest categories have shown growth of
• Azithromycin contributing to 51% of Macrolides de-grew at -13% 7% (MAT), muscle relaxants amongst smaller ones has shown
because of high growth 32% seen in 2021 due to use in COVID growth of 4%
• High growth seen from Ampicillin/ Amoxycillin 20% • Paracetamol Oral Solids have reflected degrowth at -6% ; whereas
• Carbapenems showed degrowth of -8% majorly due to Meropenem - 10% Para Liquids, Inj have shown growth of 20% and 15% resp and also
11% whereas Faropenem grew at 16% Para+Tramadol comb which grew at 14%

47%
Respiratory (Acute) Gastro - Intestinal

• MAT growth: Value: 6%; Unit: -1.5%

17% • MAT growth: Value: 11%; Unit: 2%

• Cough preparations contributing ~52% of total therapy sales have
shown growth of 5% due to Levosalbutamol & comb reflecting 27%
growth
• Cold Preparations as well as Antihistamines, systemic both grew at
9%
• Antipeptic ulcerants contributing to ~42% have reflected growth of
9%
• Laxatives have reflected growth of 12% respectively
• Pantoprazole+Domperidone and Rabeprazole+Domperidone
continue to grow at 12% and 6% respectively.

AI Pain GI Others Respi

MAT Dec 2022 vs. MAT Dec 2021 2

Source: IQVIA TSA Dec 2022
 Chronic

Driven by growth from Cardiac, Anti-diabetes, Neuro and Respi Chronic

therapies displayed growth of 9%
Chronic Acute

IPM 38% 62% 193.8

Cardiac Anti-Diabetes
• MAT growth: Value: 7%; Unit: -1.9% • MAT growth: Value: 6%; Unit: -0.1%
16%
• Statins & Hypotensives both grew 11% . They together contribute • Glimepiride + Metformin (Traditional OAD) has shown single digit
47~% of TA sales growth of 6% and -2% Unit growth
• Other Cardiac therapies viz., Betablockers, ARB have registered 32% • High growth seen from Vildagliptin 14% and Vildagliptin +
single digit growth Metformin 9%
• Anticoagulants de-grew by -11% majorly due to Enoxaparin • Sitagliptin and Sitagliptin+Metformin which went off-patent in 2022
degrowing at -33% which had a growth of 75% in 2021 17% reflected degrowth of -11% and -3% resp but showed unit growth
of 35% and 23% resp
• However Ticagrelor which contributes to 16% to Anticoagulants
reflected growth of 30% • Insulin market showed single digit growth of 4%

Respiratory (Chronic) Neuro / CNS

• MAT growth: Value: 11% and Unit: 7% 10% • MAT growth: Value: 10%; Unit: 0.2%
• The inhalation prep market continued to show good growth of 17% 24% • Anti-Depressant and Anti-Epileptics, which together constitute
pulling up the overall Chronic Resp market growth 51% of the TA, grew at 9% and 12%
• Montelukast and comb market grew at 15% • Gabapentin + Nortriptylin within Antiepileptics has shown high
growth of 24% and Brivaracetam with smaller base showed
• Montelukast + Levocetrizine Solids grew at 9% growth
fastest rate of growth of 116%
• Bilastine+Montelukast showed exceptional growth of 48%
Neuro Others Respi Anti-Diabetes Cardiac

MAT Dec 2022 vs. MAT Dec 2021 3

Source: IQVIA TSA Dec 2022
 IPM New Intro. Performance

Anti-Diabetes market showed high no of new launches in Sitagliptin and its

combination market …..owing to Sitagliptin going off patent
Year No. of new launches (IPM) Value of new launches (IPM) Avg val/ NI (IPM)
MAT Dec 2020 3266 2266.3 Cr 0.7 Cr
MAT Dec 2021 2982 1167.1 Cr 0.4 Cr
MAT Dec 2022 3032 1541.3 Cr 0.5 Cr

Cat. Molecule Total MAT No of Top 3 Brands of each molecule

No. of new launches (IPM) Avg Val/ NI
Val in Crs of launche
mol s
ANTI DIABETIC 371 1.0

RESPI 221 0.3 DAPAGLIFLOZIN PROPANEDIOL + VILDAGLIPTIN 124.9 42 ZOMELIS-D, JALRA-DP, DAPARYL V

DERMA 443 METFORMIN HYDROCHLORIDE + SITAGLIPTIN PHOSPHATE 65.9 67 ALSITA-M, SITARA-M, SITAHENZ-M
0.2 AD

VMN 451 DAPAGLIFLOZIN PROPANEDIOL + SITAGLIPTIN PHOSPHATE 60.7 54 ISTAVEL D, GLUXIT-S, OXRA-S
0.3
CARDIAC 237 0.3 ITRACONAZOLE 12.3 15 SUBITRAL, PHYTINIA, VIZITRA-XL

226 CHLOROCRESOL + CLOBETASOL PROPIONATE + MICONAZOLE

PAIN 0.3 NITRATE + NEOMYCIN
5.6 2 COSVATE-GM ++ CANZIT-MX
DERMA
IMMUNOMODULATOR 68 0.7
ALOE BARBADENSIS + CYCLOMETHICONE + LACTOBACILLUS
3.6 1 ELOVERA PRO
ANTI-INFECTIVES 123 0.5 PLANTARUM + TROLAMINE + VITAMIN E ACETATE

ANTIVIRAL 17 4.4 APTAMIL GOLD, SIMILAC PLUS, MMS

INFANT MILKS 38.5 6
GOLD
GYNAEC. 142 1.4
CALCIUM FOLINATE + CALCIUM CITRATE + COLECALCIFEROL +
VMN MAGNESIUM HYDROXIDE + MECOBALAMIN + PYRIDOXAL 5-PHOSPHATE 9.9 1 SUPRACAL 2000
GI 191 0.4 + ZINC

0.4 BORON + CALCIUM CARBONATE + COLECALCIFEROL + MAGNESIUM

CNS 200 6.9 1 TAYO RAGA
OXIDE + SOYA ISOFLAVONES + ZINC
4
NI* definition are brands launched in a period of one year. (i.e., NI for Dec 2022 are brands launched from Jan 2022 to Dec 2022)
 Geography

South and North zones continue to be highest contributing zones. Metros

and Class 1 grew at 7% each and Extra Urban market showed 5% growth
Zonal Dynamics Town Class Analysis
MAT Dec’ 22: ₹ 193,838 Cr., MAT Gr (7%) MAT Dec’ 22: ₹ 193,838 Cr., MAT Gr (7%)

(9%) North East (8%)

27% 24% (7%)
(5%) 33%
36%

22% Metro
27% West (0%) Class 1
31%
(8%) South Extra Urban
(7%)

• South & North are leading zones by contribution; South growing at 8% and North at • Extra Urban reflected growth of 5%
9% PPG with most incremental coming from Delhi, Kerala, Uttar Pradesh, Karnataka • Metros and Class 1 both showed growth of 7%
• West zone was stagnant in terms of growth. Though Goa, Gujarat, Madhya Pradesh • Metros indicated higher growths primarily led by Delhi (16%),Calcutta
reflected single digit growth. Maharashtra and Mumbai regions showed decline (10%), Hyderabad (11%), Bangalore (14%), Chennai (9%), Jaipur (12%),
resulting in stagnation in terms of growth Patna (10%) Agra (11%) and Ludhiana (13%)
• East zone’s growth of 8% was driven by all regions (West Bengal, Assam,
Jharkhand, Kolkata, Orissa, Bihar) except Chhattisgarh which de-grew by -3%
• Amongst the top 15 regions, West Bengal (13%), Kerala (12%), Uttar Pradesh
(5%), Karnataka (9%), Telangana (10%), Assam (14%), Rajasthan (10%), Kolkata
(10%), Punjab (11%), Tamil Nadu (4%) were the top growing regions.

MAT Dec 2022 vs. MAT Dec 2021 5

Source: IQVIA TSA Dec 2022
Thank You
To learn more about Market drivers,
current and emerging trends, current
growth patterns, and market challenges
contact us via https://bit.ly/3aEILzC